Evidence map›Paper›PMID 38828414›Full record

ArticleFrontiers in endocrinology2024

Relationship of postprandial fibroblast growth factor 21 with lipids, inflammation and metabolic dysfunction-associated fatty liver disease during oral fat tolerance test.

Xiaolong Li, Kunjie Zheng, Lifang Liu, Tingxue Zhang, Wei Gu, Xiaoyu Hou, Jianlin Geng, Guangyao Song

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Targeting Metabolism: Innovative Therapies for MASLD Unveiled.International journal of molecular sciences · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaolong LiDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Kunjie ZhengDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Lifang LiuDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Tingxue ZhangDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Wei GuDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaoyu HouDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
Jianlin GengDepartment of Endocrinology, Harrison International Peace Hospital, Hengshui, Hebei, China.
Guangyao SongDepartment of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) is closely associated with serum fibroblast growth factor (FGF) 21; however, previous studies have typically focused on the static fasting state, and the relationships between postprandial FGF21 levels, postprandial metabolic status, and MAFLD remain unclear. Therefore, we measured postprandial lipids, inflammatory factors, and FGF21 levels in MAFLD and further analyzed their relationship using an oral fat tolerance test (OFTT). Patients and methods: In total, 103 non-diabetic adult volunteers, including 46 patients with MAFLD, were included in this study. All participants underwent the OFTT. Venous blood samples were collected at 0, 2, 4, and 6 h. Circulating total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), hypersensitive-C reactive protein(hs-CRP) and FGF21 were assessed. Results: Serum FGF21 significantly increased in the fasting state ( Conclusion: Dyslipidemia and excessive inflammation in MAFLD are associated to FGF21 levels in the postprandial period. An abnormal postprandial FGF21 response may be an important mechanism of MAFLD.

Indexed as

Fibroblast Growth FactorsInflammationPostprandial PeriodAdultBiomarkersDietary FatsFatty Acids, NonesterifiedFemaleHumansLipidsMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseTriglyceridesBiomarkersDietary FatsFatty Acids, NonesterifiedFGF21 protein, humanfibroblast growth factor 21Fibroblast Growth FactorsLipidsTriglyceridesfibroblast growth factor 21inflammationlipidmetabolic dysfunction-associated fatty liver diseaseoral fat tolerance testpostprandial state

Identifiers

PMID38828414
PMCPMC11140040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.